The Nevada State Legislature has introduced Assembly Bill 522, aimed at expanding healthcare coverage for prediabetes and type 2 diabetes screening and treatment. The bill, presented on April 24, 2025, seeks to address the rising prevalence of diabetes among adults in the state, particularly those aged 35 to 70 with a body mass index (BMI) of 25 or greater, and individuals aged 18 and older with a BMI of 30 or greater.

Key provisions of AB 522 mandate that managed care organizations provide specific benefits related to diabetes screening and intensive behavioral interventions. Insured individuals meeting the criteria will have access to these services without facing higher deductibles, copayments, or waiting periods. The bill also prohibits insurers from penalizing healthcare providers who offer these benefits and prevents them from discouraging insured individuals from utilizing these services through financial incentives or other means.

The introduction of this bill has sparked discussions among lawmakers and healthcare advocates. Proponents argue that it is a crucial step toward improving public health and reducing long-term healthcare costs associated with untreated diabetes. Critics, however, express concerns about the potential financial implications for managed care organizations and the healthcare system as a whole.

The bill is expected to have significant social and economic implications, as diabetes management can lead to improved health outcomes and reduced healthcare expenditures over time. If passed, AB 522 will take effect for health plans issued or renewed after October 1, 2025, ensuring that these essential benefits are legally mandated.

As the legislative process unfolds, stakeholders are closely monitoring the bill's progress, anticipating debates that may shape its final form. The outcome of AB 522 could set a precedent for future healthcare legislation in Nevada, particularly regarding preventive care and chronic disease management.